A PLASMID CONTROLLING DOWN-REGULATION OF THE CRUCIAL B BURGDORFERI OSPC PROTEIN

控制重要 B 布氏 OSPC 蛋白下调的质粒

基本信息

  • 批准号:
    7716318
  • 负责人:
  • 金额:
    $ 2.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-21 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Infectivity and persistence by Borrelia burgdorferi relies stringently on regulatory events. Among these is the down-regulation of lipoprotein antigen expression, exemplified by outer surface protein C (OspC), at the advent of specific immunity. B. burgdorferi spirochetes that lack the linear plasmid (lp) 28-1 succumb to the host's immune response. We thus explored the notion that these two phenomena were relatedthat lp28-1(-) organisms failed to down-regulate OspC and thus succumbed to the appearance of anti-OspC antibody. The lp-28(-) and wild type isolates were grown for either 8 or 14 days in dialysis membrane chambers that were implanted into rat peritoneal cavities. Analysis of mRNA and protein from these cultures showed that OspC expression levels by lp28-1(-) organisms are abnormally high in vivo. A time-course analysis of OspC expression in tissues following infection implies also that temporal diminution of the dominant antigen OspC is impaired in lp28-1(-) spirochetes. Finally, passive transfer of anti-OspC monoclonal antibodies into scid mice 8 days post-infection cleared lp28-1 spirochetes, yet the wild type organisms persisted. These findings indicate that failure to down-regulate OspC by lp28-1(-) organisms render them susceptible to immune-mediated clearance. The lp28-1 plasmid must harbor one or more genes mediating OspC down-regulation.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MONICA E EMBERS其他文献

MONICA E EMBERS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MONICA E EMBERS', 18)}}的其他基金

A Multiplex Platform for Lyme Disease Diagnosis and Treatment Response
莱姆病诊断和治疗反应的多重平台
  • 批准号:
    8478039
  • 财政年份:
    2012
  • 资助金额:
    $ 2.41万
  • 项目类别:
A Multiplex Platform for Lyme Disease Diagnosis and Treatment Response
莱姆病诊断和治疗反应的多重平台
  • 批准号:
    8300508
  • 财政年份:
    2012
  • 资助金额:
    $ 2.41万
  • 项目类别:
A Multiplex Platform for Lyme Disease Diagnosis and Treatment Response
莱姆病诊断和治疗反应的多重平台
  • 批准号:
    8841437
  • 财政年份:
    2012
  • 资助金额:
    $ 2.41万
  • 项目类别:
XENODIAGNOSIS FOR EVALUATION OF ANTIMICROBIAL EFFICACY IN LYME DISEASE
用于评估莱姆病抗菌功效的异种诊断
  • 批准号:
    8358135
  • 财政年份:
    2011
  • 资助金额:
    $ 2.41万
  • 项目类别:
CUTANEOUS IMMUNITY IN LYME DISEASE
莱姆病的皮肤免疫
  • 批准号:
    8358164
  • 财政年份:
    2011
  • 资助金额:
    $ 2.41万
  • 项目类别:
XENODIAGNOSIS FOR EVALUATION OF ANTIMICROBIAL EFFICACY IN LYME DISEASE
用于评估莱姆病抗菌功效的异种诊断
  • 批准号:
    8173049
  • 财政年份:
    2010
  • 资助金额:
    $ 2.41万
  • 项目类别:
A PLASMID CONTROLLING DOWN-REGULATION OF THE CRUCIAL B BURGDORFERI OSPC PROTEIN
控制重要 B 布氏 OSPC 蛋白下调的质粒
  • 批准号:
    7958665
  • 财政年份:
    2009
  • 资助金额:
    $ 2.41万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.41万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 2.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了